Patent

Understanding of the Pharmaceutical Patent Litigation Cases in China from the Perspective of 24 Month Approval Period (Ⅰ)

The General Office of Central Committee Of The Communist Party Of China(CCCPC) and the General Office of State Council jointly issued Opinions on Deepening of Review and Approval System Reform to Encourage Medicinal and Medical Appliance Innovation, which pointed out that China m

The New Development of China Drug Patent Linkage System (Ⅱ)

On May 12, 2017, the CFDA (now the CDA) issue an “Announcement of the China Food and Drug Administration on Soliciting Opinions on the Relevant Policies on Encouraging Innovation in Drug and Medical Equipment and Protecting the Rights and Interests of Innovators"

The New Development of China Drug Patent Linkage System (Ⅰ)

The drug patent linkage system stems from America’s Hatch- Waxman Act in America, formally known as the Drug Price Competition and Patent Term Restoration Act of 1984.

New Development in Chinese Practice on Calculation of Patent Damage Awards (Ⅱ)

2. Application of “judicial hierarchical analysis method” to determine the amount of statutory compensation Case 2: Siemens v. “SIEMIVES” trademark infringement case ((2016) Zhejiang MinZhong No.699)

New Development in Chinese Practice on Calculation of Patent Damage Awards (Ⅰ)

With the progress of a new round of global boom in technology and industry, China is becoming the main battlefield of patent infringement disputes.